Patents

US 10131904 B2: Modified RNAi polynucleotides and uses thereof

Granted
2018-11-20
Filed
2009-02-11 application 12867181
Type
Utility · 8 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2′-O-methyl group at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.

Source: PVGPATDIS, file of 2026-04-10 (ipg181120.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
RXi Pharmaceuticals Corporation 17 patentsUS company or organizationMarlborough, MAPVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Pamela PavcoLongmont, CO14PVGPATDIS, file of 2026-04-10
Joanne KamensNewton, MA30PVGPATDIS, file of 2026-04-10
Tod M. WoolfSudbury, MA41PVGPATDIS, file of 2026-04-10
William SalomonWorcester, MA35PVGPATDIS, file of 2026-04-10
Anastasia KhvorovaNorthborough, MA193PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N15/111PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/04PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2018-12-07Name change
Change of name
RXI PHARMACEUTICALS CORPORATION signed 2018-11-14PHIO PHARMACEUTICALS CORP. MARLBOROUGH, MA48380/9PASDL, file of 2026-10-15
2012-05-02Release of security interest
Release of security interest
TANG CAPITAL PARTNERS, LP signed 2012-05-01RXI PHARMACEUTICALS CORPORATION WORCESTER, MA28144/110PASDL, file of 2026-10-15
2011-09-29Name change
Change of name
RNCS, INC. signed 2011-09-26RXI PHARMACEUTICALS CORPORATION WORCESTER, MA26988/874PASDL, file of 2026-10-15
2011-09-26Security interest Security interest
Security agreement
RNCS, INC. signed 2011-09-24TANG CAPITAL PARTNERS, LP SAN DIEGO, CA26976/187PASDL, file of 2026-10-15
2011-09-26Assignment
Assignment of assignor's interest
RXI PHARMACEUTICALS CORPORATION signed 2011-09-24RNCS, INC. WORCESTER, MA26969/660PASDL, file of 2026-10-15
2010-11-23Assignment
Assignment of assignor's interest
SALOMON, WILLIAM signed 2010-10-18
KAMENS, JOANNE signed 2010-10-21
KHVOROVA, ANASTASIA signed 2010-10-28
PAVCO, PAMELA A. signed 2010-11-04
WOOLF, TOD M. signed 2010-11-10
RXI PHARMACEUTICALS CORPORATION WORCESTER, MA25398/220ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.